Prognosis of Differentiated Thyroid Cancer in Relation to Serum Thyrotropin and Thyroglobulin Antibody Status at Time of Diagnosis

McLeod, Donald S A; Cooper, David S.; Ladenson, Paul W.; Ain, Kenneth B.; Brierley, James D.; Fein, Henry G.; Haugen, Bryan R.; Jonklaas, Jacqueline; Magner, James A.; Ross, Douglas S.; Skarulis, Monica C.; Steward, David L.; Maxon, Harry R.; Sherman, Steven I.

doi:10.1089/thy.2013.0062

Cited by 122 publications

(90 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From 1997-2000 and from 2005-2008, the incidence increased 5.2% per year and was highest among females below age 50 years. PTC was the main histologic type related to the incidence increase, and there was a decrease in other histological types (2).…”

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

Surgical treatment for thyroid carcinoma: retrospective study with 811 patients in a Brazilian tertiary hospital

Cavalheiro

Matos

Leite

et al. 2016

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

Objective: The aim of the present study was to describe the epidemiologic data, histological type, treatment and follow-up of the 811 patients treated for thyroid cancer in Instituto do Câncer do Estado de São Paulo (ICESP) over 5 years. Materials and methods: Retrospective analyses of electronic chart information. Results: There were 679 cases (83.7%) of papillary thyroid cancer, 61 (7.5%) of follicular carcinoma, 54 (6.7%) of medullary carcinoma, 11 (1.4%) of poorly differentiated carcinoma and 6 of anaplastic carcinoma (0.7%). The majority of patients were female (82.2%), and the mean age was 50.5 ± 15 years. Two hundred forty-two patients had disease persistence or recurrence. At the last follow-up, 629 (77.6%) patients were alive and disease free, 141 (17.4%) were alive with disease, and 41 (5.1%) were deceased, with 37 deaths related to thyroid cancer. Conclusion: This study was able to outline the profile, disease type and evolution of patients treated for thyroid cancer at a single tertiary hospital. Arch Endocrinol Metab. 2016;60(5):472-8

show abstract

Section: Introductionmentioning

confidence: 95%

“…The literature reports that less than 5% of patients die from the disease within 10 years. However, poorly differentiated and anaplastic carcinomas have a very poor prognosis, with a mean survival of less than 6 months in the anaplastic cases (1,2).…”

Section: Introductionmentioning

confidence: 99%

Surgical treatment for thyroid carcinoma: retrospective study with 811 patients in a Brazilian tertiary hospital

Cavalheiro

Matos

Leite

et al. 2016

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

show abstract

“…We were the first to publish that serum TSH is raised in patients with malignant thyroid nodules compared with those with benign disease (Boelaert et al 2006), and subsequent studies have shown that pre-operative serum TSH is proportionally higher in those with more aggressive disease (Boelaert et al 2006, Jonklaas et al 2008, Haymart et al 2009, McLeod et al 2014, Fighera et al 2015. This review aims to explore the relationship between TSH and thyroid cancer, both before and after a diagnosis of malignancy is made.…”

Section: :11mentioning

confidence: 99%

“…They suggest that as Hashimoto's disease often progresses to hypothyroidism resulting in elevated TSH concentrations and because Graves' disease is associated with TSH receptor stimulation, which is associated with thyroid cancer (Mazzaferri 2000), it follows that TSH receptor activation is the link between thyroid cancer and thyroid autoimmune disease. More recently, a study directed at assessment of anti-thyroglobulin antibody (TgAb) measured pre-operative levels in differentiated thyroid cancer patients and concluded that TgAb was not an independent predictor of DTC prognosis, once adjusted for age and gender (McLeod et al 2014). They noted that TgAb may be raised in autoimmunity and in patients exhibiting an immune response to the tumour, and may not be a true representation of thyroid autoimmune disease.…”

Section: Serum Tsh and Thyroid Autoimmunitymentioning

confidence: 99%

WOMEN IN CANCER THEMATIC REVIEW: Thyroid-stimulating hormone in thyroid cancer: does it matter?

Nieto¹,

Boelaert²

2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

Differentiated thyroid cancer is the most common endocrine malignancy and the incidence is increasing rapidly worldwide. Appropriate diagnosis and post-treatment monitoring of patients with thyroid tumours are critical. Fine needle aspiration cytology remains the gold standard for diagnosing thyroid cancer, and although there have been significant refinements to this technique, diagnostic surgery is often required for patients suspected to have malignancy. Serum thyroid-stimulating hormone (TSH) is higher in patients with malignant thyroid nodules than in those with benign disease, and TSH is proportionally increased in more aggressive tumours. Importantly, we have shown that the pre-operative serum TSH concentration independently predicts the presence of malignancy in subjects presenting with thyroid nodules. Establishing the use of TSH measurements in algorithms identifying high-risk thyroid nodules in routine clinical practice represents an exciting, cost-efficient and non-invasive approach to optimise thyroid cancer diagnosis. Binding of TSH to receptors on thyrocytes stimulates a number of growth promoting pathways both in normal and malignant thyroid cells, and TSH suppression with high doses of levothyroxine is routinely used after thyroidectomy to prevent cancer recurrence, especially in high-risk tumours. This review examines the relationship between serum TSH and thyroid cancer and reflects on the clinical potential of TSH measurements in diagnosis and disease monitoring.

show abstract

“…The data collection and analytical methods of the NTCTCS have been described elsewhere (8,9,(14)(15)(16)(17)(18)(19)(20). Briefly, 11 North American centers contributed patient data, with registration beginning in January 1987 (this data analysis captures patients registered through to 2011).…”

Section: Registry Protocol and Data Collectionmentioning

confidence: 99%

Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis

McLeod

Jonklaas

Brierley

et al. 2015

Thyroid

Self Cite

View full text Add to dashboard Cite

Background: Thyroid cancer is unique for having age as a staging variable. Recently, the commonly used age cut-point of 45 years has been questioned. Objective: This study assessed alternate staging systems on the outcome of overall survival, and compared these with current National Thyroid Cancer Treatment Cooperative Study (NTCTCS) staging systems for papillary and follicular thyroid cancer. Methods: A total of 4721 patients with differentiated thyroid cancer were assessed. Five potential alternate staging systems were generated at age cut-points in five-year increments from 35 to 70 years, and tested for model discrimination (Harrell's C-statistic) and calibration (R 2 ). The best five models for papillary and follicular cancer were further tested with bootstrap resampling and significance testing for discrimination. Results: The best five alternate papillary cancer systems had age cut-points of 45-50 years, with the highest scoring model using 50 years. No significant difference in C-statistic was found between the best alternate and current NTCTCS systems ( p = 0.200). The best five alternate follicular cancer systems had age cut-points of 50-55 years, with the highest scoring model using 50 years. All five best alternate staging systems performed better compared with the current system ( p = 0.003-0.035). There was no significant difference in discrimination between the best alternate system (cut-point age 50 years) and the best system of cut-point age 45 years ( p = 0.197). Conclusions:No alternate papillary cancer systems assessed were significantly better than the current system. New alternate staging systems for follicular cancer appear to be better than the current NTCTCS system, although they require external validation.

show abstract

Prognosis of Differentiated Thyroid Cancer in Relation to Serum Thyrotropin and Thyroglobulin Antibody Status at Time of Diagnosis

Cited by 122 publications

References 37 publications

Surgical treatment for thyroid carcinoma: retrospective study with 811 patients in a Brazilian tertiary hospital

Surgical treatment for thyroid carcinoma: retrospective study with 811 patients in a Brazilian tertiary hospital

WOMEN IN CANCER THEMATIC REVIEW: Thyroid-stimulating hormone in thyroid cancer: does it matter?

Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis

Contact Info

Product

Resources

About